Phenolic profiling of Hyphaene Thebaica by LC-ESI-Mass:Iron Nanoparticles Significance and Cytotoxic Activity

The aerial parts of Pituranthos tortuosus (Desf.) Benth and Hook (Apiaceae), growing wild in Egypt, yielded 0.8%, 0.6%, and 1.5% (v/w) of essential oil when prepared by hydrodistillation (HD), simultaneous hydrodistillation-solvent (n-pentane) extraction (Lickens-Nickerson, DE), and conventional volatile solvent extraction (preparation of the "absolute", SE), respectively. GC-MS analysis showed that the major components in the HD sample were beta-myrcene (18.81%), sabinene (18.49%), trans-iso-elemicin (12.90%), and terpinen-4-ol (8.09%); those predominent in the DE sample were terpinen-4-ol (29.65%), sabinene (7.38%), gamma-terpinene (7.27%), and beta-myrcene (5.53%); while the prominent ones in the SE sample were terpinen-4-ol (15.40%), dill apiol (7.90%), and allo-ocimene (4E,6Z) (6.00%). The oil prepared in each case was tested for its cytotoxic activity on three human cancer cell lines, i.e., liver cancer cell line (HEPG2), colon cancer cell line (HCT116), and breast cancer cell line (MCF7). The DE sample showed the most potent activity against the three human cancer cell lines (with IC50 values of 1.67, 1.34, and 3.38 microg/ml against the liver, colon, and breast cancer cell lines, respectively). Terpinen-4-ol, sabinene, gamma-terpinene, and beta-myrcene were isolated from the DE sample and subjected to a similar evaluation of cytotoxic potency; significant activity was observed.

This study determined the bioactive compounds and evaluated the antioxidant, antimicrobial, and cytotoxicity activities of Bidens pilosa aqueous and ethanolic extracts against bacterial and fungal pathogens and various human cancer cell lines. The B. pilosa leaves were extracted using ethanol and water as solvents. The aqueous (BA) and ethanolic (BE) extracts of B. pilosa were subjected to qualitative phytochemical screening. The phosphomolybdate method was used to determine the total antioxidant activity of the extracts. The antimicrobial activity of the extracts against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Candida tropicalis was determined using the Kirby-Bauer method. Lastly, the brine shrimp lethality test (BSLT) and 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay in the human breast, colon, and liver cancer cell lines were used to evaluate the cytotoxicity activities of the more potent extract. Steroids, flavonoids, tannins, saponins, alkaloids, and cyanogenic glycosides were present in B. pilosa leaf extracts. BE showed higher antioxidant and antimicrobial activities than BA. However, BSLT results showed BA was more toxic than BE based on their lethal concentration 50 (LC50) values after 24- hour exposure. MTT assay also showed that BA was more potent against the colon cancer (HCT116) cell line, followed by breast (MCF-7) and liver (Hep G2) cancer cell lines. The B. pilosa extracts possess potent antioxidant, antimicrobial, and anticancer activities. These biological activities are due to the presence of various natural products present in its leaves. Further investigations are needed to understand the pharmacological properties of B. pilosa fully.

Chemical investigation of the stems of Salacia verrucosa Wight (family Celastraceae) led to the isolation of one new (21α-hydroxyfriedelane-1,3-dione) and three known 1,3-diketofriedelane triterpenes (friedelane-1,3-dione, 26-hydroxyfriedelane-1,3-dione and 30-hydroxyfriedelane-1,3-dione), three friedelane-type triterpenes (friedelin, kokoonol and 21α-hydroxyfriedelan-3-one), and one oleanane-type triterpene (3β,22α-dihydroxyolean-12-en-29-oic acid). From the stems of Ficus foveolata (Wall. ex Miq.) Miq. (family Moraceae), two new (foveolide A and foveoeudesmenone) and two known eudesmane-type sesquiterpenes [4(15)-eudesmene-1β,6α-diol and 4(15)-eudesmene-1β,5α-diol], a new sesquiterpenoid dimer (foveolide B), one new (foveospirolide) and one known phenolic compound (ethyl rosmarinate), together with three known triterpenes (friedelin, taraxerol and betulin) were isolated. The chemical structures of these plant constituents were determined by spectroscopic analyses, including UV, IR, MS and NMR, and comparison with previously reported data. Friedelane-1,3-dione was strongly cytotoxic against human colon cancer cell line (SW620) with an IC [subscript 50] value of 2.02 µM, whereas 26-hydroxyfriedelane-1,3-dione and 21α-hydroxyfriedelan-3-one were moderately cytotoxic against colon, liver (HepG2) and gastric (KATO-III) cancer cell lines. 26-Hydroxyfriedelane-1,3-dione also exhibited moderate cytotoxicity against lung (CHAGO) and breast (BT474) cancer cell lines. Foveolide A was moderately cytotoxic against colon, liver, breast and gastric cancer cell lines, while foveolide B was specifically cytotoxic toward colon cancer cell line. In addition, foveolide A exhibited anti-tuberculosis activity against Mycobacterium tuberculosis with a minimum inhibitory concentration of 200 µM.

Peptide-based therapy has emerged as a promising avenue for treating various disorders, and recent research has highlighted the potential of anti-cancer peptides (ACPs) in cancer treatment. In this context, this study aimed to design a novel peptide incorporating a tumor-homing peptide (RGD) and C-amidation to enhance its anticancer activity, particularly against liver (HepG2) and colon (HCT-116) cancer cell lines. The primary objective was to design a peptide with improved anticancer properties by leveraging the tumor-homing capabilities of RGD and enhancing its activity through C-amidation. The study sought to evaluate the cytotoxicity of the designed peptide against red blood cells (RBCs) and normal Vero cells. Furthermore, the anticancer efficacy of the peptide was assessed in hepatocellular carcinoma (HepG2) and colon cancer (HCT-116) cell lines. The specific objectives included examining the apoptotic induction and morphological changes in treated cells compared to untreated cells. The peptide was designed using the ACPred-FL bioinformatics tool, and its cytotoxicity was assessed through hemolysis assays against RBCs and normal Vero cells. Anticancer activity was evaluated against HepG2 and HCT-116 cell lines. The analysis of apoptotic induction involved measuring the relative gene expression of oncogenic marker BCL2 and apoptotic markers (BAX, BID, CAS-8). Additionally, Cytopathological examination and Western Blot analysis were employed to study morphological changes and confirm the quantification of relevant markers. The designed peptide, consisting of twelve amino acids with a molecular mass of 1230.6233 Da and an isoelectric point of 9.81, exhibited low erythrocyte lysis and minimal toxicity to normal cells. The IC50 values demonstrated significant anticancer activity against both HepG2 (36.49±2.6 μg/mL) and HCT-116 (11.03±2.5 μg/mL) cell lines. Treated cells exhibited a significant decrease in the oncogenic marker BCL2 and an upregulation of apoptotic markers (BAX, BID, CAS-8). Western Blot analysis confirmed these results in addition to cytopathological examination that scattered apoptotic and degenerative changes. The designed peptide is considered a patent product that displayed remarkable anticancer activity against hepatocellular carcinoma and colon cancer cell lines, effectively modulating apoptotic and oncogenic markers. These findings highlight the potential of the peptide as a therapeutic agent for cancer treatment, emphasizing its clinical significance in combating liver and colon cancers. Nonetheless, further research and development are warranted to explore the translational potential of this peptide in clinical studies.

Peptides derived from high oleic acid soybean meals inhibit colon, liver and lung cancer cell growth

Purpose: To design and develop halogenated chalcone derivatives and evaluate them as anticancer agents using different cancer cell lines. Methods: Based on in silico design and docking on known target, crystal structure of the complex of interleukin-1beta converting enzyme (ICE) with a peptide based inhibitor, (3S )-N-Methanesulfonyl-3({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4-oxobutanamide (1BMQ), novel halogenated chalcone derivatives were designed (7a-h) employing LigandFit module of Accelrys (Discovery Studio, 2.1 version). Standard protocols for ligand and protein preparation were employed and their binding orientation validated using (3S)-N-Methanesulfonyl-3-({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4oxobutanamide (MNO 601), a caspase inhibitor as reference standard. Energy minimized conformers with best dock scores were considered for the identification of interacting amino acid residues with ligands. Selected derivatives were synthesized and analyzed by melting point, 1 H NMR, IR and mass spectroscopy. Their evaluation for anticancer activity was carried out using adriamycin, paclitaxel and 5fluorouracil as reference standards on prostrate (PC-3), colon (COLO-205), ovary (OVCAR-5), liver (HEP-2) and neuroblastoma (IMR-32) cancer cell lines, and % growth inhibition and half maximal inhibitory concentration (IC50) values were calculated. Results: Among synthesized compounds, 7b showed the most promising cytotoxic activity with an IC50 of 49.9 µM on colon cancer cell lines (Colo-205), followed by 7d with an IC50 of 66.6 µM against ovarian cancer cell lines (OVCAR-5). Conclusion: We report the successful synthesis, spectral characterization and in vitro anticancer evaluation of a series of novel halogenated chalcone derivatives against a number of human cancer cell lines. The findings indicate the emergence of new anticancer compounds.

Cancer is among the top global public health burdens leading to millions of deaths each year. The study aims to investigate the antiproliferative effect of Spartium junceum L. flowers on different cancer cell lines. The ethanolic extract of the flowers was prepared in the present study. Phytochemical analysis of the plant extract revealed the presence of several phenolic compounds such as cinnamic acid and its derivatives (chlorogenic, p-coumaric, ferulic acids), protocatechuic acid, epicatechin and luteolin. This extract was tested against human breast (MDA-MB-231) and liver (HepG2) cancer cell lines to find out its antiproliferative activity. It was determined that the extract was effective against both cell lines with IC50 values of 2.37 ± 0.47 and 0.98 ± 0.01 µL/mL for MDA-MB-231 and HepG2, respectively. Particularly, the extract was found to be more effective in the liver cancer cell line than the breast cancer cell line. All these obtained findings led us to believe that this medicinal plant could be a promising antiproliferative agent candidate for the treatment of human liver and breast cancers.

In this study, seven new 3(2H)-pyridazinone derivatives expected to show cytotoxic activity in liver and colon cancer cell lines were synthesized. Their structures were confirmed by the IR, 1H-NMR, 13C-NMR spectra and elementary analyses. Compunds V1-V7 were tested on HEP3B (liver cancer) and HTC116 (colon cancer) cell lines for cytotoxicity by using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium] proliferation assay. Human fibroblast cells were used as safety control in these tests. 6-[4-(2-Fluorophenyl)piperazine-1-yl]-3(2H)-pyridazinone-2-acetyl-2-(2-chlorobenzal)hydrazone (compound V3 ) was the most active agent with respect to HEP3B and HTC116 cell lines.

Cancer remains the leading cause of death worldwide, with breast cancer being the most prevalent disease diagnosed globally. Liver cancer is the fourth most common cause of death globally, while prostate cancer accounts for the second most frequent malignancy among males worldwide. The main treatment options for cancer include surgery, radiation therapy, and chemotherapy. The stem bark of Tieghemella heckelii has been exploited for its medicinal properties. On a broader scale, research on the anticancer properties of T. heckelii has not been explored. It is therefore important to investigate the anticancer potential of the leaves of T. heckelii. The goal of the study was to evaluate the in vitro anticancer activities of the leaves of T. heckelii on breast, prostate, and liver cancer cell lines. The leaves of T. heckelii were collected from Asantemanso, Akim Oda, in the eastern region of Ghana. Authenticity of the leaves was performed at the Department of Plant and Environmental Biology, University of Ghana. Aqueous and ethanol extraction were performed on the leaves of T. heckelii after grinding into fine particles, followed by low-temperature drying. Breast cancer (MDA-MB-468), liver cancer (HepG2), and normal kidney (Vero E6) cell lines were cultured in DMEM media, while prostate cancer (PC3) cell lines were cultured in RPMI medium. Anticancer activity of the leaves of T. heckelii was conducted on breast (MDA-MB-468), liver (HepG2), and prostate (PC3) cancer cell lines. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Both ethanolic and aqueous extracts demonstrated similar cytotoxicity for the HepG2 cell line, with IC50 values of about 200 μg/mL. selectivity index of > 2 was recorded by all cell lines. When compared to other cell lines, the aqueous extract for prostate cancer showed the lowest IC50 value with a selectivity of 8. In addition, the extracts showed less cytotoxic activity against the normal (Vero) cell line. Leaves of T. heckelii possess cytotoxic properties with notable selectivity against prostate (PC3) and liver (HepG2) cancer cell lines. However, findings should be evaluated in in vivo studies because biological processes can be more complex in living organisms. Further investigation should be conducted to ascertain the bioactive compounds responsible for the anticancer activity.

Background: We previously identified 14 variants of T-cell factor (TCF)-4, a key transcriptional factor in the canonical Wnt signaling pathway, from human liver cancer cell lines (Exp Cell Res 2011). The functional analysis of the variants demonstrated that the SxxSS motif played crucial roles in high tumorigenicity, resistance to hypoxia (PLoS ONE 2012), and EMT (Liver Int 2013). These findings suggest that expression levels and patterns of TCF-4 variants tightly regulate diverse phenotypes of cancer cells. Currently, we developed a novel RT-PCR system to quantitatively evaluate TCF-4 variant expressions by using the peptide nucleic acid (PNA)-directed PCR clamping method. Aim: To assess mRNA expression levels of TCF-4 variants in hepato-gastrointestinal cancer cell lines and colon cancer tissues, focusing on TCF-4J and TCF-4K with the presence (K) or absence (J) of the SxxSS motif. Methods: Thirteen cell lines used in this study were as follows: seven liver cancer; one fetus-derived immortalized hepatocyte; one gastric cancer; two pancreatic cancer; and two colon cancer cell lines. The liver cancer cell lines HAK-1A and HAK-1B are clonally sister cell lines. Sets of three forward primers and four reverse primers were used to generate templates for quantitative PCR (qPCR), and three fluorescence (FAM and Cy5)-tagged primers were applied to detect each variant. Thirty-nine resected human cancer and non-cancerous tissue pairs were used in the IRB-certified study (No. 19192). Results: All TCF-4 variants except TCF-4M and TCF-4X were specifically and reproducibly detected and quantified. Cancer cells derived from the colon and stomach highly expressed the TCF-4 variants, showing the highest expression in TCF-4J, while cancer cells from the liver and pancreas expressed relatively lower levels. There was no remarkable difference in the expression profile of TCF-4 variants between HAK-1A and HAK-1B. In colon cancer tissues, TCF-4J was significantly more expressed than TCF-4K. Conclusion: Although the variants had been identified from liver cancer cells, they were universally expressed in cells of other organs. TCF-4J, a variant responsible for aggressive cell phenotype, was prominently found in cancer cells of the digestive tract, where the canonical Wnt signal pathway is known to be constitutively active. A similar variant profile between two liver cancer cell lines with identical clonal origin suggests that the variant pattern in the cells reflects organ-specific traits rather than dynamic phenotypic changes during cancer cell dedifferentiation. Citation Format: Hironori Koga, Yasuko Imamura, Tomoya Sudo, Hiroyuki Suzuki, Toshimitsu Tanaka, Takahiko Sakaue, Atsutaka Masuda, Hideki Iwamoto, Toru Nakamura, Hirohisa Yano, Takumi Kawaguchi. Expression levels of T-cell factor-4 variants in hepato-gastrointestinal cancer cells and tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4393.

Background: Cancer is the most common malignancy in men and women globally. The tyrosine kinases and serine/threonine kinases are essential to cell mediators for extra & intracellular signal transduction processes and play a key role in cell proliferation, differentiation, migration, metabolism, and programmed cell deaths. In this context, kinases are considered as a potential drug target for cancer therapy. Methods: In the present study, a two-dimensional (2D) quantitative structure-activity relationship (2D-QSAR) was performed to analyze anticancer activities of 28 quinazolinyl-arylurea (QZA) derivatives based on the liver (BEL-7402), stomach (MGC-803), and colon (HCC-827) cancer cell lines using multiple linear regression (MLR) analysis. It was accomplished using 2D-QSAR analysis on the available IC50 data of 28 molecules based on theoretical molecular descriptors to develop predictive models that correlate structural features of QZA derivatives to their anticancer activities. A suitable set of molecular descriptors, such as constitutional, topological, geometrical, electrostatic, and quantum-chemical descriptors were calculated to represent the structural features of compounds. The genetic algorithm (GA) method was used to identify the important molecular descriptors to build the QSAR models and used to predict the anti-cancer activities. Results and Discussion: The obtained 2D-QSAR models were vigorously validated using various statistical metrics using leave-one-out (LOO) and external test set prediction approaches. The best predictive models by MLR gave highly significant square of correlation coefficient (R2 train) values of 0.799, 0.815, and 0.779 for the training set, and the correlation coefficients (R2 test) were obtained 0.885, 0.929, and 0.774 for the test set for the liver, stomach, and colon cancer cell lines. The models also demonstrated good predictive power confirmed by the high value of cross-validated correlation coefficient Q2 value of 0.663, 0.717, and 0.671 for three different cancer cell lines. Importantly, the model's quality was judged as well based on mean absolute error (MAE) criteria, and the results were consistent with proposed limits by Golbraikh and Tropsha. Conclusion: The QSAR results of the study indicated that the proposed models were robust and free from chance correlation. This study indicated that maxHBint7, SpMax8_Bhm, and ETA_Beta_ns_d have positively contributed descriptors for anti-cancer activity in the liver, stomach, and colon cancer cell lines and a detailed mechanistic interpretation of each model revealed important structural features that were responsible for favorable or unfavorable for anticancer activity. The predictive ability of the proposed models was good and may be useful for developing more potent quinazolinyl-arylurea compounds as anti-cancer agents.

BackgroundGlutaminase 2 (Gls2) is a p53 target gene and is known to play an important role in energy metabolism. Gls2 has been reported to be downregulated in human hepatocellular carcinomas (HCC). However, the underlying mechanism responsible for its downregulation is still unclear. Here, we investigated Gls2 expression and its promoter methylation status in human liver and colon cancers.MethodsmRNA expression of Gls2 was determined in human liver and colon cancer cell lines and HCC tissues by real-time PCR and promoter methylation was analyzed by methylation-specific PCR (MSP) and validated by bisulfite genome sequencing (BGS). Cell growth was determined by colony formation assay and MTS assay. Statistical analysis was performed by Wilcoxon matched-pairs test or non-parametric t test.ResultsFirst, we observed reduced Gls2 mRNA level in a selected group of liver and colon cancer cell lines and in the cancerous tissues from 20 HCC and 5 human colon cancer patients in comparison to their non-cancerous counter parts. Importantly, the lower level of Gls2 in cancer cells was closely correlated to its promoter hypermethylation; and chemical demethylation treatment with 5-aza-2′-deoxycytidine (Aza) increased Gls2 mRNA level in both liver and colon cancer cells, indicating that direct epigenetic silencing suppressed Gls2 expression by methylation. Next, we further examined this correlation in human HCC tissues, and 60% of primary liver tumor tissues had higher DNA methylation levels when compared with adjacent non-tumor tissues. Detailed methylation analysis of 23 CpG sites at a 300-bp promoter region by bisulfite genomic sequencing confirmed its methylation. Finally, we examined the biological function of Gls2 and found that restoring Gls2 expression in cancer cells significantly inhibited cancer cell growth and colony formation ability through induction of cell cycle arrest.ConclusionsWe provide evidence showing that epigenetic silencing of Gls2 via promoter hypermethylation is common in human liver and colon cancers and Gls2 appears to be a functional tumor suppressor involved in the liver and colon tumorigenesis.

Although a number of chemicals have been isolated from Strychnos nux-vomica, only a few have been evaluated for their biological significance. As a part of our drug discovery programme for cytotoxic agents from Indian medicinal plants, a novel cytotoxic agent, loganin 1 was isolated from the fruit pulp of S. nux-vomica. The loganin 1 showed significant anticancer activity against the human liver (WRL-68), colon (COLO-320 and CaCo2), ovarian (PA-1) and breast (MCF-7) cancer cell lines. Loganin 1 was further chemically transformed into eleven semi-synthetic derivatives 2–12 of which 2′,3′,4′,7-tetra-O-acetyl-6′-O-(3′′′, 4′′′, 5′′′)-trimethoxybenzoyl loganin 11 and 2′,3′,4′,7-tetra-O-acetyl-6′-O-lauroyl loganin 6 derivatives showed eight, 13 and three times while 2′,3′,4′,7-tetra-O-acetyl-6′-O-lauroyl loganin 6 showed equal, 13 and two times more activity against human suspension colon (CaCo2), adherent colon (COLO-320) and liver (WRL-68) cancer cell lines, respectively, than the known anticancer agent, vinblastine. The other analogues (except 4, 8 and 9) and loganin also showed marginal to moderate anticancer activity against the five tested human cancer cell lines.

Objective: To facilitate using the CRISPR/Cas9 gene editing system in human liver and gallbladder cancer cells, we established Cas9 stably expressed human liver and gallbladder cancer cell lines, and validated the gene editing activity of Cas9. Methods: Human liver cancer cell lines (Huh7, PLC/PRF/5, HepG2, Hep3b, SK-HEP-1 and Li-7), human cholangiocarcinoma cells (RBE) and human gallbladder cancer cells (GBC-SD) were infected with 3 Cas9-expressing lentivirus vectors (pLv-EF1α-Cas9-Flag-Neo, pLv-EF1α-Cas9-Flag-Puro, Cas9m1.1), respectively, and Cas9 stably expressed colonies were screened and selected. We extracted the genomic DNA and protein, validated the stable expression of Cas9 by using genomic polymerase chain reaction (PCR) and western blot. Three of cell lines were further infected with Lv-EF1α-mCherry. Then mCherry positive cells were sorted by flow cytometry and infected with designed guide RNA (gRNA) vectors which targeted mCherry gene. Subsequently the gene editing activity of Cas9 was detected by genomic PCR, fluorescence microscopic observation and flow cytometry analysis. Results: One hundred Cas9-expressing human liver and gallbladder cancer cell lines were selected. Among them, 35 cell lines expressed Cas9-Neo, 25 expressed Cas9-puro, and 40 expressed mutant Cas9 (mCas9). We also established 3 cell lines with stable expression of mCherry (Huh7-mCas9-M, PLC/PRF/5-Cas9-M and SK-HEP-1-Cas9-M). The results of genomic PCR and sequencing showed that by lentiviral infection with 2 types of designed gRNA, the long fragment deletion of mCherry gene was found in these 3 cell lines. Moreover, mCherry(-)EGFP(+) cells infected with 2 types of gRNA were observed by fluorescence microscope. The results of flow cytometry showed that mCherry(-)EGFP(+) cells accounted from 0.3% to 93.6%. Conclusion: We successfully establish 100 human liver and gallbladder cancer cell lines with stable expression of Cas9 protein and validate their activities of gene editing.

Disclosure: P. Ramaraj: None. Our previous in-vitro studies involving vitamins (vitamin-A and vitamin-D3) and steroids (progesterone and RU-486) pointed to a combination of vitamin-A and RU-486 as an efficient combo to decrease human melanoma cell growth. We extended this combo treatment to human liver cancer cell (Hep-G2) line. The aim was to check whether vit-A and RU-486 combo would also decrease human liver cancer cell line growth. Liver cancer (Hep-G2) cells were plated in a 96 well plate overnight. Following day, vit-A and RU-486 were added either alone or in different combinations for 48 hrs. After 48 hrs, cell viability and percentage of cell growth were monitored by the MTT assay. Supernatants were collected for Elisarray and quantitation of cytokine(s) by Elisa. Individual vit-A and RU-486 treatments showed a dose-dependent decrease in cell growth. Though various combinations of vit-A (50, 75, 100 μM) and RU-486 (10, 50 100 μM) also showed a decrease in cell growth, an experimentally significant decrease in cell growth was observed at vit-A 75 μM and RU-486 50 μM combination. This combo resulted in 24% cell growth compared to straight vit-A (75 μM) at 44% cell growth and RU-486 (50 μM) at 35% cell growth. Thus, this combo inhibited liver cancer cell growth also. In the future effect of this combo on normal liver cell line and the cytokine(s) if any, playing a central role in cell growth would be identified by Elisarray and quantitated by Elisa. Presentation: 6/3/2024